BOSENTAN

The U.S. FDA approved bosentan on 20th of Nov 2001. Bosentan is used to treat pulmonary arterial hypertension (PAH).

Bosentan is used to treat pulmonary arterial hypertension (high blood pressure).

Bosentan is available in two different strengths, 62.5mg and 125mg tablets which can be consumed orally. Your physician will decide the dosage and frequency of this injection based on the severity of your disease and other factors.

The common side effects that are experienced while you are on the treatment are Bosentan headache, oedema, respiratory tract infection, inflamed nose passage, joint pain, irregular heartbeats, diarrhoea and low blood pressure. Report your doctor immediately, if you experience abnormal liver function, anaemia, allergic reaction (skin inflammation, itching and rash).

Inform your doctor if you are allergic to bosentan or any of the ingredients present in them. Inform your doctor if you have any history of liver problems, psoriasis, or hypoglycemia (low blood pressure).

Inform your doctor about your prescribed and non-prescribed medicine and take a proper diet while under medication. It will be helpful for him to treat you based on your previous medical history or make some dose adjustments. It is not recommended for pediatric patients with systemic sclerosis and ulcer disease. It may affect the fertility of the male individual and foetus of the pregnant female individual. So, consult your doctor if you are planning to get pregnant or think you may be pregnant while breastfeeding.

Your doctor will advise you to check the blood pressure and hemoglobin level because bosentan may cause low blood pressure and anemia as a side effect. Inform your doctor if you have a liver problem, are pregnant women planning to get pregnant, or think you may be pregnant before taking the medicine. It may be contraindicated to liver patients or pregnant women. Speak with your doctor about your medical history before going to start the medicine.

Pharmadox Healthcare Ltd., Electronic Medicines Compendium (EMC), [Revised on June 2018] [Accessed on 30th Sep 2023], Bosentan Dr. Reddy's 62.5 mg Film-Coated Tablets - Patient Information Leaflet (PIL) - (emc) (medicines.org.uk) Actelion Pharmaceuticals US, Inc., US Food and Drug Administration, [Revised on Sep 2017], [Accessed on 20th Oct 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209279s000lbl.pdf Good and Gilman’s, The pharmacological basis of therapeutics, protein synthesis inhibitors and miscellaneous antibacterial agents, 13th edition, 76, 580-583, 841.